Michael Benkowitz - 15 Mar 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
PRESIDENT AND COO
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 17:10:36 UTC
Previous filing
24 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BENKOWITZ MICHAEL PRESIDENT AND COO C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING /s/ John S. Hess, Jr. under Power of Attorney 17 Mar 2026 0001673232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise +17,790 17,790 15 Mar 2026 by Trust F1, F2
transaction UTHR Common Stock Options Exercise +15,592 +86% 33,752 15 Mar 2026 by Trust F1, F2
transaction UTHR Common Stock Tax liability -7,837 -23% $536.12* 25,915 15 Mar 2026 by Trust F2, F3
transaction UTHR Common Stock Tax liability -6,869 -27% $536.12* 19,046 15 Mar 2026 by Trust F2, F3
holding UTHR Common Stock 2,710 15 Mar 2026 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Restricted Stock Units Options Exercise -17,790 -100% $0.000000* 0 15 Mar 2026 Common Stock 17,790 by Trust F1, F2, F5
transaction UTHR Restricted Stock Units Options Exercise -15,592 -100% $0.000000* 0 15 Mar 2026 Common Stock 15,592 by Trust F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
F2 Securities held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power.
F3 Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.
F4 Includes 62 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.
F5 Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.